Emerson Collective Cancer Research Fund Symposium
September 18, 2017
Berg Hall, Li Ka Shing Center

11:30 am–12:00 pm  Optional Lunch
12:00–12:10 pm  Welcome Remarks
12:10–12:35 pm  Reprogramming Cancer Cells into Antigen Presenting Cells for Cancer Vaccination
 Ravi Majeti
12:35–1:00 pm  Combining Radiation and Targeted Immunotherapy for Effective Cancer Treatment
 Jennifer R. Cochran
1:00–1:25 pm  Identification of Novel Exhaustion Checkpoints in Chimeric Antigen Receptor Expressing T Cells Using CRISPR/Cas9 Gene Disruption
 Crystal L. Mackall, Rachel C. Lynn
1:25–1:50 pm  Toward Small-Molecule Immune Checkpoint Inhibitors
 Peter S. Kim
1:50–2:15 pm  An Effective Therapy for Bladder Cancer
 Philip Beachy, Joseph Liao
2:15–2:40 pm  Modeling Cancer Immunotherapy in Patient Derived Tumor Organoid Cultures
 Christina Curtis, Calvin Kuo
2:40–3:05 pm  CCRL2 antagonism: a novel approach to cancer immunotherapy
 Brian Zabel
3:05–3:30 pm  Therapeutic targeting of RAS mutant breast cancer cells
 Michael F. Clarke
3:30–3:45 pm  Break
3:45–4:00 pm  Targeting PKA Signaling In Neuroendocrine Tumors
 Julien Sage, Parag Mallick, Pamela Kunz
4:00–4:15 pm  Developing precision microbiota-directed therapeutics for chemoimmunotherapy-associated
 Ami Bhatt, Robert Negrin
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15–4:30 pm</td>
<td>Identifying Small Molecules that can Restore a Global Immune Response Against Cancer</td>
<td>Dean Felsher</td>
</tr>
<tr>
<td>4:30–4:45 pm</td>
<td>Leveraging Tumor Evolutionary Dynamics To Predict and Prevent Metastasis</td>
<td>Christina Curtis, Calvin Kuo</td>
</tr>
<tr>
<td>4:45–5:00 pm</td>
<td>Therapeutic suppression of PanACEs: the earliest cellular lesion in pancreatic adenocarcinoma</td>
<td>Steven Artandi</td>
</tr>
<tr>
<td>5:00–5:15 pm</td>
<td>Overcoming the epigenetic rigidity of cancer through iPS cell reprogramming informed by network</td>
<td>Marius Wernig, Sylvia Plevritis</td>
</tr>
<tr>
<td>5:15–5:30 pm</td>
<td>Potentiating Immunotherapy against Malignant Brain Tumors through Targeted Suppression of Claudin-5 to Modulate the Blood-Brain Barrier</td>
<td>Gerald Grant, Siddhartha Mitra</td>
</tr>
<tr>
<td>5:30–5:40 pm</td>
<td>Closing Remarks</td>
<td></td>
</tr>
</tbody>
</table>